TrialA Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Trial details
- Registry ID
- NCT06767683
- Phase
- Phase 2, Phase 3
Drug research
ALKS 2680, 14mg
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683 | Alkermes, Inc. | Phase 2, Phase 3 | Recruiting | 2028-06Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |